{
  "doc_id": "5fa6981c5c42338b0b4f5f40d8f44776c6ff36a33bd681531ce71f1660400a10",
  "chunk_entities": [
    {
      "chunk_id": "707433e25d630b53df6e5482abedfd5d",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "Drug Abuse",
          "context": "National Institute on Drug Abuse"
        }
      ]
    },
    {
      "chunk_id": "5e4e759866a368650b92c7c1c6812eae",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "monoamine releasers",
          "context": "administration of stimulant-like medications (e.g. monoamine releasers)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine addiction",
          "context": "cocaine and methamphetamine addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "methamphetamine addiction",
          "context": "cocaine and methamphetamine addiction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce withdrawal symptoms",
          "context": "reduce withdrawal symptoms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "prevent relapse",
          "context": "prevent relapse"
        },
        {
          "entity_type": "Effect",
          "entity_name": "abuse liability",
          "context": "possess abuse liability"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine (DA)",
          "context": "activation of mesolimbic dopamine (DA) neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin (5-HT)",
          "context": "add in serotonin (5-HT)-releasing properties"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitory influence",
          "context": "provide an inhibitory influence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA/5-HT releasers",
          "context": "development of dual DA/5-HT releasers"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorders",
          "context": "treatment of substance use disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic cocaine abuse",
          "context": "withdrawal from chronic cocaine or alcohol abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol abuse",
          "context": "withdrawal from chronic cocaine or alcohol abuse"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stimulant effects",
          "context": "dampen DA-mediated stimulant effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT2C receptors",
          "context": "the \u2018anti-stimulant\u2019 role of 5-HT2C receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-stimulant role",
          "context": "the \u2018anti-stimulant\u2019 role"
        },
        {
          "entity_type": "Effect",
          "entity_name": "adverse effects",
          "context": "potential adverse effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "data with PAL-287, a novel non-amphetamine DA/5-HT-releasing agent"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "a novel non-amphetamine DA/5-HT-releasing agent"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA/5-HT-releasing agent",
          "context": "a novel non-amphetamine DA/5-HT-releasing agent"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppresses cocaine self-administration",
          "context": "suppresses cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "positive reinforcing properties",
          "context": "lacks positive reinforcing properties"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine addictions",
          "context": "treatment of cocaine and alcohol addictions"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol addictions",
          "context": "treatment of cocaine and alcohol addictions"
        },
        {
          "entity_type": "Disease",
          "entity_name": "obesity",
          "context": "as well as for obesity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "attention deficit disorder",
          "context": "attention deficit disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depression",
          "context": "and depression"
        }
      ]
    },
    {
      "chunk_id": "fa24184795b17e6575f4b97a14548820",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "Keywords: alcohol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "Keywords: amphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "Keywords: cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Keywords: dopamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "Keywords: serotonin"
        }
      ]
    },
    {
      "chunk_id": "5268763697f5f696c251e9886636a663",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "dual dopamine (DA)/serotonin (5-HT) releasers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "dual dopamine (DA)/serotonin (5-HT) releasers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "releasers",
          "context": "dopamine (DA)/serotonin (5-HT) releasers"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stimulant addiction",
          "context": "medications for stimulant addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol addiction",
          "context": "possibly alcohol addiction"
        }
      ]
    },
    {
      "chunk_id": "1d21f261392efbd361304acd60d7267d",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction disorders",
          "context": "medications for addiction disorders"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "drugs such as cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamines",
          "context": "cocaine and amphetamines"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cardiovascular stimulation",
          "context": "including cardiovascular stimulation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mood elevation",
          "context": "mood elevation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased need for sleep",
          "context": "a decreased need for sleep"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "high doses",
          "context": "At high doses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "disordered thoughts",
          "context": "such as disordered thoughts"
        }
      ]
    },
    {
      "chunk_id": "e0c3dbfbe43af13f308bf949f7895af0",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "reuptake inhibitors",
          "context": "reuptake inhibitors and substrate-type releasers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "substrate-type releasers",
          "context": "reuptake inhibitors and substrate-type releasers"
        }
      ]
    },
    {
      "chunk_id": "54188172c7a6b92f330b827dccbfbdad",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "The top row shows amphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "amphetamine and methamphetamine."
        },
        {
          "entity_type": "Compound",
          "entity_name": "phentermine",
          "context": "The bottom row shows phentermine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chlorphenamine",
          "context": "phentermine, chlorphenamine, and fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "chlorphenamine, and fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "m-fluoroamphetamine",
          "context": "m-fluoroamphetamine (PAL-353)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "p-methylamphetamine",
          "context": "p-methylamphetamine (PAL-313)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "1-naphthyl-2-aminopropane",
          "context": "1-naphthyl-2-aminopropane (PAL-287)"
        }
      ]
    },
    {
      "chunk_id": "098b56fb607de8522a2f6f2d630bd075",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "stimulants",
          "context": "Chemical structures of stimulants discussed"
        }
      ]
    },
    {
      "chunk_id": "373e0a0b0e91145a4c78062620948992",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "transmitter molecules",
          "context": "transmitter molecules from the synapse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Substrate-type releasers",
          "context": "Substrate-type releasers bind to transporter proteins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "transporter proteins",
          "context": "bind to transporter proteins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cytoplasm",
          "context": "transported into the cytoplasm of nerve terminals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "transmitter 'releasers'",
          "context": "transmitter 'releasers' are often referred to as transporter 'substrates'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "transporter 'substrates'",
          "context": "referred to as transporter 'substrates'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Releasers",
          "context": "Releasers elevate extracellular transmitter concentrations"
        },
        {
          "entity_type": "Compound",
          "entity_name": "transmitter",
          "context": "promote efflux of transmitter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter 2 (VMAT2)",
          "context": "interactions with the vesicular monoamine transporter 2 (VMAT2)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ionic currents",
          "context": "but ionic currents, oligomerization and reversal of normal transport function appear to be involved"
        },
        {
          "entity_type": "Effect",
          "entity_name": "oligomerization",
          "context": "ionic currents, oligomerization and reversal of normal transport function appear to be involved"
        },
        {
          "entity_type": "Effect",
          "entity_name": "transport function",
          "context": "reversal of normal transport function"
        },
        {
          "entity_type": "Compound",
          "entity_name": "substrate-type releasing agents",
          "context": "Because substrate-type releasing agents must be transported into nerve terminals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "reuptake inhibitors",
          "context": "reuptake inhibitors can block the effects of releasers"
        }
      ]
    },
    {
      "chunk_id": "739019506863bb79bcc7d89e6a0fec8c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxytryptamine",
          "context": "existence of 5-HT deficits"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine addiction",
          "context": "in cocaine addicts"
        },
        {
          "entity_type": "Disease",
          "entity_name": "major depression",
          "context": "resembling major depression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suicidal ideation",
          "context": "prevalence of suicidal ideation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suicide attempts",
          "context": "suicide attempts"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxytryptamine",
          "context": "importance of 5-HT dysfunction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depression",
          "context": "mediating depression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suicide",
          "context": "mediating depression and suicide"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxytryptamine",
          "context": "decreased synaptic 5-HT"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine withdrawal",
          "context": "in cocaine and alcohol withdrawal states"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol withdrawal",
          "context": "and alcohol withdrawal states"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stimulant withdrawal",
          "context": "withdrawing from stimulant"
        },
        {
          "entity_type": "Effect",
          "entity_name": "depressed mood",
          "context": "depressed mood"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suicidal ideations",
          "context": "suicidal ideations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "obsessive thoughts",
          "context": "obsessive thoughts"
        },
        {
          "entity_type": "Effect",
          "entity_name": "intense craving",
          "context": "intense craving"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anhedonia",
          "context": "anhedonia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased impulsivity",
          "context": "increased impulsivity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "deficits in monoamine systems"
        }
      ]
    },
    {
      "chunk_id": "3363929e19d1bdb8822dee231bd8508d",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "the 5-HT releaser fenfluramine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "5-HT releaser",
          "context": "the 5-HT releaser fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "responding for cocaine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases responding for cocaine",
          "context": "fenfluramine decreases responding for cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phentermine",
          "context": "administration of phentermine"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "75% decrease",
          "context": "produces a 75% decrease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decrease in cocaine self-administration",
          "context": "produces a 75% decrease in cocaine self-administration"
        }
      ]
    },
    {
      "chunk_id": "62675204c6afc820766a5babedc84411",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "decrease stimulant abuse",
          "context": "decrease stimulant abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stimulant abuse",
          "context": "decrease stimulant abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "abused drugs",
          "context": "with the abused drugs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "stimulant medication",
          "context": "the stimulant medication serves"
        },
        {
          "entity_type": "Effect",
          "entity_name": "normalize neurochemical deficits",
          "context": "normalize neurochemical deficits"
        },
        {
          "entity_type": "Compound",
          "entity_name": "abused stimulant",
          "context": "to the abused stimulant"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nicotine dependence",
          "context": "for nicotine dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "nicotine",
          "context": "nicotine dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "opioid dependence",
          "context": "and opioid dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioid",
          "context": "and opioid dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine dependence",
          "context": "treatment of cocaine dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "of cocaine dependence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "abuse liability",
          "context": "exhibit inherent abuse liability"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "mesolimbic DA neurons"
        }
      ]
    },
    {
      "chunk_id": "608b42dc4cba7c53e1699c690da26a60",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "release [^{3}\\text{H}]DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin",
          "context": "than [^{3}\\text{H}]5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "e.g. amphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phentermine",
          "context": "and phentermine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "extracellular DA"
        },
        {
          "entity_type": "Effect",
          "entity_name": "release",
          "context": "drugs that release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase",
          "context": "increase endogenous extracellular DA"
        }
      ]
    },
    {
      "chunk_id": "de55bb27b736b486b5727fd154119b0b",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "5-HT in vivo."
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA agonists",
          "context": "indirect DA agonists"
        },
        {
          "entity_type": "Effect",
          "entity_name": "locomotor stimulants",
          "context": "strong locomotor stimulants"
        },
        {
          "entity_type": "Effect",
          "entity_name": "self-administration behaviour",
          "context": "support self-administration behaviour."
        },
        {
          "entity_type": "Compound",
          "entity_name": "[^{3}\\text{H}]5-HT",
          "context": "release [^{3}\\text{H}]5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "[^{3}\\text{H}]DA",
          "context": "than [^{3}\\text{H}]DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "e.g. fenfluramine and chlorphentermine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chlorphentermine",
          "context": "and chlorphentermine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "extracellular 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "extracellular DA."
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT agonists",
          "context": "indirect 5-HT agonists"
        },
        {
          "entity_type": "Effect",
          "entity_name": "motor activity",
          "context": "minimal motor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "self-administration behaviour",
          "context": "do not support self-administration behaviour."
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-stimulant effect",
          "context": "The anti-stimulant effect"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT releasers",
          "context": "effect of 5-HT releasers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "conditioned place preference (CPP)",
          "context": "conditioned place preference (CPP) assay"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "dose of fenfluramine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "positive CPP",
          "context": "reduces the positive CPP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phentermine",
          "context": "induced by phentermine."
        }
      ]
    },
    {
      "chunk_id": "30f8a86b00b9d3a882a7db7899d606d6",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "anti-stimulant",
          "context": "anti-stimulant effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin releasers",
          "context": "effects of 5-HT releasers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin",
          "context": "extracellular 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin receptor subtypes",
          "context": "activate multiple 5-HT receptor subtypes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "modulate DA function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stimulant",
          "context": "stimulant and reinforcing properties"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reinforcing",
          "context": "reinforcing properties"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "drugs such as cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "cocaine and methamphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "mesolimbic DA neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "mesolimbic DA neurons reside"
        }
      ]
    },
    {
      "chunk_id": "28ad247f9dd438702aa5e00b55549fab",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "Amphetaminea"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.3 mg/kg i.p.",
          "context": "45 (0.3 mg/kg i.p.)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.3 mg/kg i.p.",
          "context": "224 (0.3 mg/kg i.p.)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administered",
          "context": "YesStrong"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor activation Strong",
          "context": "YesStrong"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phentermine",
          "context": "Phenterminea"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.p.",
          "context": "232 (1.0 mg/kg i.p.)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.p.",
          "context": "156 (1.0 mg/kg i.p.)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administered",
          "context": "YesStrong"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor activation Strong",
          "context": "YesStrong"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-353",
          "context": "PAL-353c"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.v.",
          "context": "170 (1.0 mg/kg i.v.)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.v.",
          "context": "432 (1.0 mg/kg i.v.)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administered",
          "context": "YesStrong"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor activation Strong",
          "context": "YesStrong"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Fenfluramine",
          "context": "Fenfluraminea"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.p.",
          "context": "215 (1.0 mg/kg i.p.)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.p.",
          "context": "20 (1.0 mg/kg i.p.)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administered",
          "context": "NoNone"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor activation None",
          "context": "NoNone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Chlorphentermine",
          "context": "Chlorphenterminea"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.p.",
          "context": "228 (1.0 mg/kg i.p.)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.p.",
          "context": "86 (1.0 mg/kg i.p.)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administered",
          "context": "NoNone"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor activation None",
          "context": "NoNone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phentermine",
          "context": "Phentermine + fenfluraminea"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Fenfluramine",
          "context": "Phentermine + fenfluraminea"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 + 1.0 mg/kg i.p.",
          "context": "222 (1.0 + 1.0 mg/kg i.p.)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 + 1.0 mg/kg i.p.",
          "context": "144 (1.0 + 1.0 mg/kg i.p.)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administered",
          "context": "NoWeak"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor activation Weak",
          "context": "NoWeak"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-313",
          "context": "PAL-313c"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.v.",
          "context": "544 (1.0 mg/kg i.v.)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.v.",
          "context": "130 (1.0 mg/kg i.v.)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administered Weak",
          "context": "WeakWeak"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor activation Weak",
          "context": "WeakWeak"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "PAL-287b"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.v.",
          "context": "464 (1.0 mg/kg i.v.)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg i.v.",
          "context": "133 (1.0 mg/kg i.v.)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administered",
          "context": "NoWeak"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor activation Weak",
          "context": "NoWeak"
        }
      ]
    },
    {
      "chunk_id": "4b5042ae3c22504b1332516a6cedfefd",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "increasing extracellular 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reinforcing effects",
          "context": "reduce reinforcing and locomotor effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "locomotor effects",
          "context": "reduce reinforcing and locomotor effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "increases in extracellular DA"
        }
      ]
    },
    {
      "chunk_id": "264f324093510c28569cbf079eb8cd8c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxytryptamine",
          "context": "5-HT neurons in the midbrain raphe nuclei"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxytryptamine",
          "context": "5-HT neurons innervate various regions"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxytryptamine",
          "context": "5-HT nerve terminals are uniquely positioned"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "mesolimbic DA neurons"
        }
      ]
    },
    {
      "chunk_id": "a69bc2330b04aecbcdf9901bd8dfa90f",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "inhibitory influence",
          "context": "provide a strong inhibitory influence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ro 60-0175",
          "context": "5-HT2C agonist Ro 60-0175"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits DA cell firing",
          "context": "markedly inhibits DA cell firing"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases extracellular levels of DA",
          "context": "decreases extracellular levels of DA"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces locomotor activity",
          "context": "reduces locomotor activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "produced by cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SB 242084",
          "context": "5-HT2C antagonist SB 242084"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases burst firing of DA cells",
          "context": "increases burst firing of DA cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tonic inhibition",
          "context": "provide tonic inhibition"
        }
      ]
    },
    {
      "chunk_id": "8b3993a1de8464757d6ce027b05f8855",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramines",
          "context": "fenfluramines, norfenfluramines and positive control drugs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "norfenfluramines",
          "context": "fenfluramines, norfenfluramines and positive control drugs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "activate",
          "context": "ability to activate a mitogenic 5-HT receptor subtype"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mitogenic",
          "context": "mitogenic 5-HT receptor subtype"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "mitogenic 5-HT receptor subtype"
        }
      ]
    },
    {
      "chunk_id": "00602f763f19f9b012d9d9621e8da917",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramines",
          "context": "fenfluramines have low affinity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "low affinity",
          "context": "have low affinity for all 5-HT2 receptor subtypes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "norfenfluramines",
          "context": "norfenfluramines displayed high affinity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "high affinity",
          "context": "displayed high affinity and efficacy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "efficacy",
          "context": "high affinity and efficacy at the 5-HT2B receptor subtype"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "10-50 nM",
          "context": "(K_i = 10\text{--}50\text{ nM})"
        }
      ]
    },
    {
      "chunk_id": "ce39fac1c8f10bec78ae7e77f7a6e2a9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "(\u00b1)-Fenfluramine",
          "context": "(\u00b1)-Fenfluramine5216\u00b14234134\u00b112813183\u00b1637"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(+)-Fenfluramine",
          "context": "(+)-Fenfluramine11,107\u00b123035099\u00b111736245\u00b1874"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(-)-Fenfluramine",
          "context": "(-)-Fenfluramine5463\u00b16005713\u00b122853415\u00b1922"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(\u00b1)-Norfenfluramine",
          "context": "(\u00b1)-Norfenfluramine2316\u00b127852.1\u00b121557\u00b161"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(+)-Norfenfluramine",
          "context": "(+)-Norfenfluramine1516\u00b115011.2\u00b17.3324\u00b112"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(-)-Norfenfluramine",
          "context": "(-)-Norfenfluramine3841\u00b161447.8\u00b130.6814\u00b198"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ergotamine",
          "context": "Ergotamine9.0\u00b11.03.0\u00b10.412\u00b11.5"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Methysergide",
          "context": "Methysergide15.0\u00b14.09.1\u00b14.91.8\u00b10.2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Methylergonovine",
          "context": "Methylergonovine12.6\u00b11.00.49\u00b10.1612.4\u00b11.0"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Fluoxetine",
          "context": "Fluoxetine299\u00b1535030\u00b1196050\u00b110"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Norfluoxetine",
          "context": "Norfluoxetine638\u00b11085063\u00b11974286\u00b160"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Trazodone",
          "context": "Trazodone19.8\u00b12.473.6\u00b136402\u00b144"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mCPP",
          "context": "mCPP391\u00b1473.2\u00b11.059\u00b111"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "5-HT614\u00b1744.0\u00b11.912.2\u00b11.3"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phentermine",
          "context": "Phentermine>10,000>10,000>10,000"
        }
      ]
    },
    {
      "chunk_id": "89304a0bfc13351053b779b550bc9088",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "Functional activity",
          "context": "Functional activity of test drugs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT2",
          "context": "at 5-HT2 receptors"
        }
      ]
    },
    {
      "chunk_id": "d6abe988e1c0db745b99f54e543713ef",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramines",
          "context": "fenfluramines increase the risk"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "developing IPAH"
        }
      ]
    },
    {
      "chunk_id": "b261139371bea9fdf729ebdbad57e2f5",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "vasoconstriction",
          "context": "pulmonary arterial vasoconstriction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hyperplasia",
          "context": "and hyperplasia that leads to severe hypertension"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hypertension",
          "context": "leads to severe hypertension"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "The pathogenesis of IPAH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "involvement of 5-HT and SERT proteins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT proteins",
          "context": "involvement of 5-HT and SERT proteins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT substrate",
          "context": "the SERT substrate activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "fenfluramine-induced IPAH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramines",
          "context": "fenfluramines increase the risk of IPAH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT",
          "context": "stimulating SERT-mediated release of 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pulmonary dysfunction",
          "context": "cause pulmonary dysfunction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "VHD",
          "context": "to explain VHD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT2B receptors",
          "context": "activation of 5-HT2B receptors"
        }
      ]
    },
    {
      "chunk_id": "3a483a860877ea40e62005015647f8af",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "plasma levels of 5-HT in rats"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "measure plasma levels of 5-HT in whole blood samples"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "baseline plasma 5-HT levels in rats"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.22 nM",
          "context": "found to be 0.22 nM"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1 nM",
          "context": "about 1 nM when corrected"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "systemic administration of fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "MDMA and other amphetamines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamines",
          "context": "other amphetamines evokes"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases in plasma 5-HT",
          "context": "evokes transient dose-dependent increases in plasma 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "increases in plasma 5-HT ranging"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "4 to 20 nM",
          "context": "ranging from 4 to 20 nM"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase plasma 5-HT",
          "context": "ability of drugs to increase plasma 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "increase plasma 5-HT is directly correlated"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase SERT-mediated 5-HT release",
          "context": "ability to increase SERT-mediated 5-HT release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT",
          "context": "increase SERT-mediated 5-HT release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "SERT-mediated 5-HT release in neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT",
          "context": "platelet SERT proteins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "fenfluramine and other 5-HT releasers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "other 5-HT releasers are able to acutely increase plasma 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase plasma 5-HT",
          "context": "able to acutely increase plasma 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "absolute levels of 5-HT are well below"
        },
        {
          "entity_type": "Effect",
          "entity_name": "contract pulmonary arteries",
          "context": "required to contract pulmonary arteries"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stimulate mitogenesis",
          "context": "or stimulate mitogenesis"
        }
      ]
    },
    {
      "chunk_id": "88f10e138c083c48e016e93a537b8a8a",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "5-HT releasers",
          "context": "chronic administration of 5-HT releasers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "increase plasma 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase plasma 5-HT",
          "context": "can persistently increase plasma 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "infusions of fenfluramine"
        }
      ]
    },
    {
      "chunk_id": "175ac8e246ed2c19193e9fb3f3b1f4f7",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "much higher 5-HT concentrations are needed"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "10 nM",
          "context": "cells is about 10 nM"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stimulate mitogenic responses",
          "context": "needed to stimulate mitogenic responses in rat pulmonary artery smooth muscle cells"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "chronic fenfluramine elevates baseline plasma 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "elevates baseline plasma 5-HT",
          "context": "chronic fenfluramine elevates baseline plasma 5-HT to less than 5 nM"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "elevates baseline plasma 5-HT to less than 5 nM"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "less than 5 nM",
          "context": "elevates baseline plasma 5-HT to less than 5 nM in rats"
        },
        {
          "entity_type": "Effect",
          "entity_name": "fenfluramine-induced increases",
          "context": "fenfluramine-induced increases in plasma 5-HT are below the concentrations"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "fenfluramine-induced increases in plasma 5-HT are below the concentrations"
        },
        {
          "entity_type": "Disease",
          "entity_name": "pulmonary side effects",
          "context": "known to cause pulmonary side effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Fenfluramine-induced elevations",
          "context": "Fenfluramine-induced elevations of plasma 5-HT are also much lower"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "Fenfluramine-induced elevations of plasma 5-HT are also much lower"
        },
        {
          "entity_type": "Effect",
          "entity_name": "produce VHD",
          "context": "required to produce VHD in rats exposed to exogenous 5-HT"
        },
        {
          "entity_type": "Disease",
          "entity_name": "VHD",
          "context": "required to produce VHD in rats exposed to exogenous 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "exposed to exogenous 5-HT (580\u2013974 nM)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "580\u2013974 nM",
          "context": "exogenous 5-HT (580\u2013974 nM)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "the 5-HT hypothesis cannot explain the mechanism"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "mechanism of fenfluramine-associated IPAH or VHD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "VHD",
          "context": "mechanism of fenfluramine-associated IPAH or VHD"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "two- to fourfold increases",
          "context": "two- to fourfold increases in plasma 5-HT could be enough"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "two- to fourfold increases in plasma 5-HT could be enough"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stimulate mitogenic responses",
          "context": "enough to stimulate mitogenic responses in susceptible individuals"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase the risk",
          "context": "increase the risk of developing IPAH"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "increase the risk of developing IPAH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "lithium",
          "context": "treatment with lithium or MAO inhibitors produces two- to fourfold increases"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO inhibitors",
          "context": "treatment with lithium or MAO inhibitors produces two- to fourfold increases"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "two- to fourfold increases",
          "context": "MAO inhibitors produces two- to fourfold increases in plasma 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "produces two- to fourfold increases in plasma 5-HT without increasing the risk"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increasing the risk",
          "context": "without increasing the risk of IPAH"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "without increasing the risk of IPAH"
        }
      ]
    },
    {
      "chunk_id": "8d0f8dcb51d6846a717565bc65c4e7cd",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "fenfluramine-associated IPAH"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "fenfluramine-associated IPAH"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "animal models of IPAH"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hypoxia",
          "context": "induction of hypoxia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "fenfluramine-associated IPAH"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "fenfluramine-associated IPAH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "fenfluramine might cause IPAH"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "fenfluramine might cause IPAH"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "development of IPAH"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hypoxic",
          "context": "in a hypoxic mouse model"
        },
        {
          "entity_type": "Compound",
          "entity_name": "norfenfluramine",
          "context": "stereoisomers of norfenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT2B agonists",
          "context": "potent and selective 5-HT2B agonists"
        },
        {
          "entity_type": "Disease",
          "entity_name": "VHD",
          "context": "produce VHD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "increase the risk of IPAH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methysergide",
          "context": "include methysergide"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ergotamine",
          "context": "ergotamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "pergolide",
          "context": "pergolide"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cabergoline",
          "context": "cabergoline"
        }
      ]
    },
    {
      "chunk_id": "c1ffd50c57471cb24d810908cc9c7277",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "administration of fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "\\alpha-fenfluramine",
          "context": "or \\alpha-fenfluramine"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "high-dose administration",
          "context": "high-dose administration of fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "depletion of 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "long-term depletion of Serotonin (5-HT)",
          "context": "can cause long-term depletion of 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT",
          "context": "loss of SERT binding sites"
        },
        {
          "entity_type": "Effect",
          "entity_name": "loss of SERT binding sites",
          "context": "loss of SERT binding sites"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "fenfluramine-induced 5-HT deficits"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "fenfluramine-induced 5-HT deficits"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Serotonin (5-HT) deficits",
          "context": "fenfluramine-induced 5-HT deficits"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotoxicity",
          "context": "evidence for neurotoxicity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "fenfluramine-induced 5-HT depletions"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "fenfluramine-induced 5-HT depletions"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Serotonin (5-HT) depletions",
          "context": "fenfluramine-induced 5-HT depletions"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "acute 5-HT release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "acute Serotonin (5-HT) release",
          "context": "acute 5-HT release has been implicated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT uptake blockers",
          "context": "5-HT uptake blockers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "synthesis inhibitors",
          "context": "synthesis inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "long-term 5-HT depletions"
        },
        {
          "entity_type": "Effect",
          "entity_name": "prevent long-term Serotonin (5-HT) depletions",
          "context": "can prevent long-term 5-HT depletions"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT substrates",
          "context": "not all SERT substrates"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "deplete 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "deplete Serotonin (5-HT)",
          "context": "substrates deplete 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mCPP",
          "context": "mCPP interacts with SERT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT",
          "context": "interacts with SERT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "release 5-HT from neurons"
        },
        {
          "entity_type": "Effect",
          "entity_name": "release Serotonin (5-HT) from neurons",
          "context": "release 5-HT from neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "\\alpha-fenfluramine",
          "context": "equipotent with \\alpha-fenfluramine"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "repeated high-dose administration",
          "context": "repeated high-dose administration of mCPP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mCPP",
          "context": "administration of mCPP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "tissue levels of 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "fails to affect postmortem tissue levels of Serotonin (5-HT)",
          "context": "mCPP fails to affect postmortem tissue levels of 5-HT"
        }
      ]
    },
    {
      "chunk_id": "d47eab322b0e07df0ad12e2adfff742c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "fenfluramine causes profound loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "loss of 5-HT",
          "context": "profound loss of 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "loss of 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT",
          "context": "SERT-mediated 5-HT release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "5-HT release",
          "context": "SERT-mediated 5-HT release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "5-HT depletion",
          "context": "long-term 5-HT depletion"
        }
      ]
    },
    {
      "chunk_id": "b3edff64c00ddb379d6620449284d29c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "5-HT releasers",
          "context": "adverse effects of 5-HT releasers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SERT substrates",
          "context": "development of SERT substrates as pharmacotherapies"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA/5-HT releasers",
          "context": "designing dual DA/5-HT releasers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "devoid of fenfluramine-like adverse effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phenylethylamine",
          "context": "distinct from the phenylethylamine structure"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine-like agents",
          "context": "shared by amphetamine-like agents"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "non-amphetamine 5-HT releasers have a reduced capacity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "non-amphetamine 5-HT releasers",
          "context": "as non-amphetamine 5-HT releasers have a reduced capacity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "adverse effects",
          "context": "adverse effects of 5-HT releasers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pharmacotherapies",
          "context": "development of SERT substrates as pharmacotherapies"
        },
        {
          "entity_type": "Effect",
          "entity_name": "adverse effects",
          "context": "fenfluramine-like adverse effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "5-HT2B agonist activity",
          "context": "lack 5-HT2B agonist activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotoxic effects",
          "context": "causing neurotoxic effects"
        },
        {
          "entity_type": "Disease",
          "entity_name": "VHD",
          "context": "prevent the risk of VHD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "IPAH",
          "context": "possibly IPAH"
        }
      ]
    },
    {
      "chunk_id": "f3a4c71678d371c8c4c4bf7d78a37e33",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "\\alpha-fenfluramine",
          "context": "administration of \\alpha-fenfluramine (d-FEN)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "d-FEN",
          "context": "administration of \\alpha-fenfluramine (d-FEN)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mCPP",
          "context": "administration of \\alpha-fenfluramine (d-FEN) or mCPP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "tissue levels of 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxyindoleacetic acid",
          "context": "its metabolite 5-hydroxyindoleacetic acid (5-HIAA)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HIAA",
          "context": "its metabolite 5-hydroxyindoleacetic acid (5-HIAA)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "10 \\mumol/kg",
          "context": "at doses of 10 or 30 \\mumol/kg"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "30 \\mumol/kg",
          "context": "at doses of 10 or 30 \\mumol/kg"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases in extracellular 5-HT",
          "context": "produce equivalent increases in extracellular 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "saline",
          "context": "compared to saline-treated group"
        }
      ]
    },
    {
      "chunk_id": "be3c1fa204d1fe03e278412a1d79c839",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Amine",
          "context": "Dialysate Amine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine (DA)",
          "context": "DA (% baseline)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "5-HT (% baseline)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Ambulation",
          "context": "Ambulation (cm)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Stereotypy",
          "context": "Stereotypy (events)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "Effects of PAL-287"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurochemical parameters",
          "context": "on neurochemical and locomotor parameters"
        },
        {
          "entity_type": "Effect",
          "entity_name": "locomotor parameters",
          "context": "on neurochemical and locomotor parameters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amine",
          "context": "dialysate amine concentrations"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine (DA)",
          "context": "for DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin (5-HT)",
          "context": "and 5-HT over time"
        },
        {
          "entity_type": "Effect",
          "entity_name": "ambulation",
          "context": "shows ambulation (cm)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stereotypy",
          "context": "and stereotypy (events)"
        }
      ]
    },
    {
      "chunk_id": "f43712c6ca99d243814087984163e882",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "Effects of PAL-287"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurochemical parameters",
          "context": "on neurochemical and locomotor parameters"
        },
        {
          "entity_type": "Effect",
          "entity_name": "locomotor parameters",
          "context": "on neurochemical and locomotor parameters"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1 mg/kg",
          "context": "injections of 1 mg/kg PAL-287"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "1 mg/kg PAL-287"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "3 mg/kg",
          "context": "followed by 3 mg/kg"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "Concentrations of DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "and 5-HT in dialysate samples"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "Baseline levels of DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "and 5-HT were"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.43 \u00b1 0.07 pg/5 \u00b5l",
          "context": "DA and 5-HT were 0.43 \u00b1 0.07"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.27 \u00b1 0.06 pg/5 \u00b5l",
          "context": "and 0.27 \u00b1 0.06 pg/5 \u00b5l"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Locomotor parameters",
          "context": "Locomotor parameters are mean"
        },
        {
          "entity_type": "Effect",
          "entity_name": "ambulation",
          "context": "distance traveled in cm (ambulation)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stereotypy",
          "context": "repetitive movements (stereotypy)"
        }
      ]
    },
    {
      "chunk_id": "d141ff97b8e39f3e7bf86dc91db523a4",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "Cocaine (inj/session)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "PAL-287 (inj/session)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Sal",
          "context": "Sal ~5 ~5"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "mg/kg/inj",
          "context": "Drug Dose (mg/kg/inj)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "inj/session",
          "context": "Cocaine (inj/session)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~5 inj/session",
          "context": "Sal ~5 ~5"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.01 mg/kg/inj",
          "context": "0.01 ~55* ~5"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~55* inj/session",
          "context": "0.01 ~55* ~5"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.03 mg/kg/inj",
          "context": "0.03 ~45* ~5"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~45* inj/session",
          "context": "0.03 ~45* ~5"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.1 mg/kg/inj",
          "context": "0.1 ~25* ~10"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~25* inj/session",
          "context": "0.1 ~25* ~10"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~10 inj/session",
          "context": "0.1 ~25* ~10"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.3 mg/kg/inj",
          "context": "0.3 ~15* ~10"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~15* inj/session",
          "context": "0.3 ~15* ~10"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "mg/kg/hr",
          "context": "Dose PAL-287 (mg/kg/hr)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.1 mg/kg/hr",
          "context": "0.1 ~90 ~100"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~90 %",
          "context": "0.1 ~90 ~100"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~100 %",
          "context": "0.1 ~90 ~100"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.32 mg/kg/hr",
          "context": "0.32 ~80 ~100"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~80 %",
          "context": "0.32 ~80 ~100"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.0 mg/kg/hr",
          "context": "1.0 ~5* ~40*"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~5* %",
          "context": "1.0 ~5* ~40*"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "~40* %",
          "context": "1.0 ~5* ~40*"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.01 mg/kg/inj",
          "context": "Cocaine (0.01 mg/kg/inj)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1 gm pellets",
          "context": "Food (1 gm pellets)"
        }
      ]
    },
    {
      "chunk_id": "7b2be919fcbd22a9d66fff4c903a6159",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "Effects of PAL-287 in the monkey self-administration assay."
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "Self-administration of cocaine and PAL-287 by rhesus monkeys."
        },
        {
          "entity_type": "Compound",
          "entity_name": "saline",
          "context": "compared to saline-injected control"
        },
        {
          "entity_type": "Effect",
          "entity_name": "self-administration",
          "context": "Effects of PAL-287 in the monkey self-administration assay."
        }
      ]
    },
    {
      "chunk_id": "84b0c5deb9ccfd550d8548bcc03a3b52",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "Our findings with PAL-287 in monkeys"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppression of cocaine self-administration",
          "context": "suppression of cocaine self-administration produced by d-amphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "d-amphetamine",
          "context": "produced by d-amphetamine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reducing cocaine self-administration",
          "context": "selectivity in reducing cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "d-amphetamine",
          "context": "formulation of d-amphetamine is effective"
        },
        {
          "entity_type": "Effect",
          "entity_name": "maintaining cocaine addicts in treatment",
          "context": "effective in maintaining cocaine addicts in treatment"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reducing illicit cocaine use",
          "context": "reducing illicit cocaine use"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "agents such as PAL-287"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mixed DA/5-HT-releasing activity",
          "context": "which have mixed DA/5-HT-releasing activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "therapeutic effects",
          "context": "will possess the therapeutic effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine-type monoamine releasers",
          "context": "effects of amphetamine-type monoamine releasers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "minimizing the adverse effects",
          "context": "minimizing the adverse effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phenethylamine structure",
          "context": "associated with the phenethylamine structure"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dual DA/5-HT releasers",
          "context": "observations that dual DA/5-HT releasers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppress alcohol ingestion",
          "context": "releasers suppress alcohol ingestion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "that PAL-287 or similar agents"
        }
      ]
    },
    {
      "chunk_id": "f7a131a0b3f48442c08655d370849fb0",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "alcohol addiction",
          "context": "alcohol addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "treatment with DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "and 5-HT releasers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "releasers",
          "context": "5-HT releasers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "blocks alcohol withdrawal seizures",
          "context": "releasers blocks alcohol withdrawal seizures"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol withdrawal seizures",
          "context": "blocks alcohol withdrawal seizures"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PAL-287",
          "context": "to refine PAL-287"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce its potency",
          "context": "to reduce its potency"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT2B receptors",
          "context": "potency at 5-HT2B receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhance monoamine release",
          "context": "drugs that enhance monoamine release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "acting as substrates",
          "context": "acting as substrates at multiple transporters"
        }
      ]
    },
    {
      "chunk_id": "2247895d58a9f60c63ac70cb44ea9956",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "Dopamine and drug addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug addiction",
          "context": "Dopamine and drug addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT(2C) receptors",
          "context": "Role of 5-HT(2C) receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "central dopamine function"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SB 242084",
          "context": "SB 242084, a selective serotonin2C receptor antagonist"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin2C receptor antagonist",
          "context": "selective serotonin2C receptor antagonist"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases dopaminergic transmission",
          "context": "increases dopaminergic transmission"
        },
        {
          "entity_type": "Compound",
          "entity_name": "RO 60-0175",
          "context": "RO 60-0175 inhibits mesolimbic dopaminergic function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits mesolimbic dopaminergic function",
          "context": "RO 60-0175 inhibits mesolimbic dopaminergic function"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin(2C) receptors",
          "context": "through serotonin(2C) receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "3,4-methylenedioxymethamphetamine",
          "context": "3,4-methylenedioxymethamphetamine abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "valvular heart disease",
          "context": "valvular heart disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin transporter",
          "context": "Induction of serotonin transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "mitogenic action of serotonin"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mitogenic action",
          "context": "mitogenic action of serotonin"
        },
        {
          "entity_type": "Disease",
          "entity_name": "pulmonary hypertension",
          "context": "in pulmonary hypertension"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "serotonin-induced smooth muscle hyperplasia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "smooth muscle hyperplasia",
          "context": "serotonin-induced smooth muscle hyperplasia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin transporter",
          "context": "Serotonin transporter overexpression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "smooth muscle hyperplasia",
          "context": "pulmonary artery smooth muscle hyperplasia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "primary pulmonary hypertension",
          "context": "in primary pulmonary hypertension"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mCPP",
          "context": "Effects of mCPP on the extracellular concentrations"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "concentrations of serotonin and dopamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "concentrations of serotonin and dopamine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Hyperlocomotive effects",
          "context": "Hyperlocomotive and discriminative stimulus effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "discriminative stimulus effects",
          "context": "discriminative stimulus effects of cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "effects of cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin(2C) (5-HT(2C)) receptors",
          "context": "control of serotonin(2C) (5-HT(2C)) receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Aminorex",
          "context": "Aminorex to fen/phen"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fen/phen",
          "context": "Aminorex to fen/phen"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin 5-HT2B receptors",
          "context": "valvular serotonin 5-HT2B receptors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cardiopathy",
          "context": "in the cardiopathy associated with fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "associated with fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamines",
          "context": "action of amphetamines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT2C receptor agonist",
          "context": "the 5-HT2C receptor agonist Ro60-0175"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ro60-0175",
          "context": "the 5-HT2C receptor agonist Ro60-0175"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces cocaine-induced locomotor activity",
          "context": "reduces cocaine-induced locomotor activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cocaine-induced locomotor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine self-administration",
          "context": "cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT(2A) receptor antagonist",
          "context": "the 5-HT(2A) receptor antagonist M100907"
        },
        {
          "entity_type": "Compound",
          "entity_name": "M100907",
          "context": "the 5-HT(2A) receptor antagonist M100907"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT(2C) receptor antagonist",
          "context": "the 5-HT(2C) receptor antagonist SB242084"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SB242084",
          "context": "the 5-HT(2C) receptor antagonist SB242084"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cocaine-induced locomotor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "locomotor activity",
          "context": "cocaine-induced locomotor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine self-administration",
          "context": "cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine-induced reinstatement of responding",
          "context": "cocaine-induced reinstatement of responding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "aminorex",
          "context": "use of aminorex and pulmonary hypertension"
        },
        {
          "entity_type": "Disease",
          "entity_name": "pulmonary hypertension",
          "context": "and pulmonary hypertension"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "Cocaine use disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "use disorders",
          "context": "Cocaine use disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "suicidal ideation",
          "context": "and suicidal ideation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Abstinence symptomatology",
          "context": "Abstinence symptomatology and psychiatric diagnosis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "in cocaine abusers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Serotonergic responsiveness",
          "context": "Serotonergic responsiveness in human cocaine users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "in human cocaine users"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Inhibition of cocaine self-administration",
          "context": "Inhibition of cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fluoxetine",
          "context": "by fluoxetine or D-fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D-fenfluramine",
          "context": "or D-fenfluramine combined with phentermine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phentermine",
          "context": "combined with phentermine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phentermine/fenfluramine",
          "context": "Phentermine/fenfluramine decreases cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases cocaine self-administration",
          "context": "decreases cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine reuptake inhibitors",
          "context": "Effects of dopamine reuptake inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "food- and cocaine-maintained responding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin(2C) receptors",
          "context": "Serotonin(2C) receptors tonically suppress the activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppress the activity",
          "context": "tonically suppress the activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dopaminergic",
          "context": "mesocortical dopaminergic and adrenergic"
        },
        {
          "entity_type": "Effect",
          "entity_name": "adrenergic",
          "context": "dopaminergic and adrenergic"
        },
        {
          "entity_type": "Effect",
          "entity_name": "serotonergic",
          "context": "but not serotonergic, pathways"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "Cocaine and methamphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "and methamphetamine: differential addiction rates"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "differential addiction rates"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "approaches to cocaine abuse treatment"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine abuse",
          "context": "cocaine abuse treatment"
        }
      ]
    },
    {
      "chunk_id": "56f037687b805892b4ee0e2f35c32d68",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "methylphenidate",
          "context": "for cocaine dependence: methylphenidate."
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine dependence",
          "context": "for cocaine dependence: methylphenidate."
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dextroamphetamine",
          "context": "Dextroamphetamine for cocaine-dependence treatment"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine-dependence",
          "context": "Dextroamphetamine for cocaine-dependence treatment"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Agonist-like",
          "context": "Agonist-like or antagonist-like treatment"
        },
        {
          "entity_type": "Effect",
          "entity_name": "antagonist-like",
          "context": "Agonist-like or antagonist-like treatment"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine dependence",
          "context": "treatment for cocaine dependence with methadone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methadone",
          "context": "with methadone for heroin dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "heroin dependence",
          "context": "for heroin dependence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Agonist-like",
          "context": "Agonist-like, replacement pharmacotherapy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "replacement pharmacotherapy",
          "context": "replacement pharmacotherapy for stimulant abuse and dependence."
        },
        {
          "entity_type": "Disease",
          "entity_name": "stimulant abuse",
          "context": "for stimulant abuse and dependence."
        },
        {
          "entity_type": "Disease",
          "entity_name": "dependence",
          "context": "stimulant abuse and dependence."
        },
        {
          "entity_type": "Disease",
          "entity_name": "stimulant abuse",
          "context": "The science of stimulant abuse."
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT(2C) receptors",
          "context": "role of 5-HT(2C) receptors on cocaine- and food-maintained behavior."
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine-maintained behavior",
          "context": "on cocaine- and food-maintained behavior."
        },
        {
          "entity_type": "Compound",
          "entity_name": "Aminorex",
          "context": "Aminorex and pulmonary hypertension."
        },
        {
          "entity_type": "Disease",
          "entity_name": "pulmonary hypertension",
          "context": "Aminorex and pulmonary hypertension."
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "Long-term serotonin administration induces heart valve disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "heart valve disease",
          "context": "induces heart valve disease in rats."
        },
        {
          "entity_type": "Effect",
          "entity_name": "Mitogenic",
          "context": "Mitogenic and secretory responses of human valve interstitial cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "secretory responses",
          "context": "secretory responses of human valve interstitial cells to vasoactive agents."
        },
        {
          "entity_type": "Compound",
          "entity_name": "vasoactive agents",
          "context": "to vasoactive agents."
        },
        {
          "entity_type": "Effect",
          "entity_name": "monoamine oxidase inhibition",
          "context": "Role of monoamine oxidase inhibition and monoamine depletion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "monoamine depletion",
          "context": "monoamine oxidase inhibition and monoamine depletion in fenfluramine-induced neurotoxicity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "in fenfluramine-induced neurotoxicity and serotonin release."
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotoxicity",
          "context": "fenfluramine-induced neurotoxicity and serotonin release."
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "neurotoxicity and serotonin release."
        },
        {
          "entity_type": "Effect",
          "entity_name": "serotonin release",
          "context": "and serotonin release."
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoaminergic agonists",
          "context": "effects of monoaminergic agonists on alcohol intake"
        },
        {
          "entity_type": "Effect",
          "entity_name": "alcohol intake",
          "context": "on alcohol intake in rats fed a tryptophan-enhanced diet."
        },
        {
          "entity_type": "Compound",
          "entity_name": "tryptophan",
          "context": "fed a tryptophan-enhanced diet."
        },
        {
          "entity_type": "Effect",
          "entity_name": "alcohol consumption",
          "context": "Alterations in alcohol consumption, withdrawal seizures"
        },
        {
          "entity_type": "Disease",
          "entity_name": "withdrawal seizures",
          "context": "alcohol consumption, withdrawal seizures, and monoamine transmission"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "and monoamine transmission in rats treated with phentermine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phentermine",
          "context": "treated with phentermine and 5-hydroxy-L-tryptophan."
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxy-L-tryptophan",
          "context": "and 5-hydroxy-L-tryptophan."
        },
        {
          "entity_type": "Effect",
          "entity_name": "Neuroendocrine effects",
          "context": "Neuroendocrine effects of D-fenfluramine and bromocriptine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D-fenfluramine",
          "context": "of D-fenfluramine and bromocriptine following repeated smoked cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "bromocriptine",
          "context": "and bromocriptine following repeated smoked cocaine in humans."
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "repeated smoked cocaine in humans."
        },
        {
          "entity_type": "Disease",
          "entity_name": "Aortic and mitral valve disease",
          "context": "Aortic and mitral valve disease induced by ergotamine therapy"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ergotamine",
          "context": "induced by ergotamine therapy for migraine"
        },
        {
          "entity_type": "Disease",
          "entity_name": "migraine",
          "context": "therapy for migraine: a case report"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Nicotine",
          "context": "Nicotine medications for smoking cessation."
        },
        {
          "entity_type": "Effect",
          "entity_name": "smoking cessation",
          "context": "for smoking cessation."
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "Increased plasma serotonin in primary pulmonary hypertension."
        },
        {
          "entity_type": "Disease",
          "entity_name": "primary pulmonary hypertension",
          "context": "in primary pulmonary hypertension."
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin",
          "context": "Serotonin and drug reward: focus on 5-HT2C receptors."
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug reward",
          "context": "Serotonin and drug reward: focus on 5-HT2C receptors."
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT2C receptors",
          "context": "focus on 5-HT2C receptors."
        },
        {
          "entity_type": "Effect",
          "entity_name": "Serotonergic modulation",
          "context": "Serotonergic modulation of the behavioral effects of cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "behavioral effects of cocaine in the squirrel monkey."
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "combined dopamine and serotonin transporter inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "dopamine and serotonin transporter inhibitors on cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "transporter inhibitors",
          "context": "serotonin transporter inhibitors on cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine self-administration",
          "context": "on cocaine self-administration in rhesus monkeys."
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxytryptamine",
          "context": "receptors for 5-hydroxytryptamine (serotonin)."
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "5-hydroxytryptamine (serotonin)."
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT receptors",
          "context": "diversity of 5-HT receptors."
        },
        {
          "entity_type": "Disease",
          "entity_name": "Addiction",
          "context": "Addiction: a disease of learning and memory."
        },
        {
          "entity_type": "Compound",
          "entity_name": "trazodone",
          "context": "concentrations of trazodone and its active metabolite m-chlorophenylpiperazine."
        },
        {
          "entity_type": "Compound",
          "entity_name": "m-chlorophenylpiperazine",
          "context": "active metabolite m-chlorophenylpiperazine."
        },
        {
          "entity_type": "Compound",
          "entity_name": "Neurotransmitter transporters",
          "context": "Neurotransmitter transporters and their impact on the development of psychopharmacology."
        },
        {
          "entity_type": "Disease",
          "entity_name": "Drug addiction",
          "context": "Drug addiction as a pathology of staged neuroplasticity."
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuroplasticity",
          "context": "pathology of staged neuroplasticity."
        },
        {
          "entity_type": "Compound",
          "entity_name": "phentermine",
          "context": "combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "phentermine and fenfluramine reduced cocaine withdrawal symptoms"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine withdrawal symptoms",
          "context": "reduced cocaine withdrawal symptoms in an open trial."
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alcoholism",
          "context": "Alcoholism: allostasis and beyond."
        },
        {
          "entity_type": "Effect",
          "entity_name": "allostasis",
          "context": "Alcoholism: allostasis and beyond."
        },
        {
          "entity_type": "Compound",
          "entity_name": "ethanol",
          "context": "Neurocircuitry targets in ethanol reward and dependence."
        },
        {
          "entity_type": "Effect",
          "entity_name": "ethanol reward",
          "context": "in ethanol reward and dependence."
        },
        {
          "entity_type": "Disease",
          "entity_name": "dependence",
          "context": "ethanol reward and dependence."
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "Function of the serotonin 5-hydroxytryptamine 2B receptor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-hydroxytryptamine 2B receptor",
          "context": "serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension."
        },
        {
          "entity_type": "Disease",
          "entity_name": "pulmonary hypertension",
          "context": "2B receptor in pulmonary hypertension."
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alcohol dependence",
          "context": "Alcohol dependence and gene x environment interaction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "emotion regulation",
          "context": "environment interaction in emotion regulation: is serotonin the link?."
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "is serotonin the link?."
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "Repeated cocaine exposure inhibits the adrenocorticotropin hormone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "adrenocorticotropin hormone",
          "context": "inhibits the adrenocorticotropin hormone"
        }
      ]
    }
  ],
  "total_entities": 630,
  "extraction_date": "2026-02-01T08:20:01.642631+00:00"
}